SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

May 18, 2011 07:00 ET

Radient Pharmaceuticals to Exhibit Onko-Sure® Cancer Test at the American Society of Clinical Oncology (ASCO) Annual Meeting

Marks RPC's 3rd Medical Conference Participation This Year

TUSTIN, CA--(Marketwire - May 18, 2011) - Radient Pharmaceuticals Corporation "RPC" (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the Company will exhibit its FDA-cleared Onko-Sure® cancer test at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3‐6, 2011. RPC will be located at booth 3101 in the exhibition hall. ASCO's 2010 Annual Meeting had a total of 32,700 attendees, including 26,600 members of the worldwide oncology community. As with last year's ASCO Meeting, it is expected that this year's ASCO Meeting will consist of educational and scientific sessions that offer cutting-edge information on the diagnosis and treatment of patients with cancer. RPC's Onko-Sure® cancer test kit is cleared by the FDA for colo-rectal cancer treatment and recurrence monitoring.

ASCO is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. With nearly 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer‐reviewed journals. ASCO's overarching goal is improving cancer care and prevention.

RPC's Director of Oncology, Dr. Afsaneh Motamed-Khorasani and Mr. Christopher Gee, Director of International Sales & Marketing, will be participating and exhibiting at the Meeting.

"Participating in ASCO 2011 is another step forward in increasing awareness of Onko-Sure® through outreach to key opinion leaders on a national and international level. Providing published clinical study results and our product's strengths at scientific conferences is a key component of building adoption rates for Onko-Sure® globally," stated RPC's Director of Oncology, Dr. Motamed-Khorasani.

Mr. Douglas MacLellan, RPC's CEO, added, "As a cancer test that is in use and cleared to market in numerous territories across the world, we benefit from presenting Onko-Sure® to the international cancer care and research community attending ASCO. By having our science and marketing executives available at the event we seek to have meaningful discussions with physicians, medical oncologists, cancer advocacy groups, and healthcare professionals involved in cancer research and testing. It's also a great opportunity to build relationships with new healthcare and lab partners internationally."

This is the 3rd scientific conference attended by RPC in 2011. The Company plans to increase its presence at national and international conferences in the future. In January, RPC presented Onko-Sure® at the BIO Asia Partnering Conference in Tokyo. In February, RPC provided a poster presentation featuring lung cancer study results at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO) in Lugano, Switzerland.

For additional information on Radient Pharmaceuticals Corporation and its products please visit: or send an e-mail to For Investor Relations contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colo-rectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit

Forward LookingStatements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements.